Financings

MediWound sells $15 million of shares below market in H.C. Wainwright bought deal

MDWD

The $12.50 price sits under both the November 2 close and the $13.475 strike on warrants expiring this month. Cash fell to $28.4 million at September 30.

Investor Chat

Scorecard

MDWDEquity
Deal Terms: 5/10, Fair termsHow favorable this deal is for the company and existing shareholders, compared with similar financings. · Terms are estimated from available structured facts. Unobserved components use the median prior; transaction linkage is incomplete. · As of 2026-11-05
Fair terms
Investor Impact: 8.2/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-05
Very highHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-05
Mixed record
Investment Attractiveness: 4.3/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-05
Mixed

Equity: share financing

By the aibio.space news desk

San Francisco seen from a ferry
San Francisco seen from a ferry. Photo: Alfred Twu, CC0, via Wikimedia Commons. The picture shows the field, not the companies named.

MediWound agreed on November 3 to sell 1,200,000 ordinary shares to H.C. Wainwright & Co., LLC at $12.50 each in a firm commitment bought deal, raising approximately $15 million before fees. The price sits below the $13.50 last sale on November 2 and below the $13.475 exercise price on warrants covering about 2.13 million shares that expire on November 27, 2026. In our reading, a sale priced under the strike gives those warrant holders less reason to pay $13.475 before the deadline unless the shares trade above it. In the company's favor, MediWound, led by Chief Executive Officer Ofer Gonen, says the EscharEx Phase III trial remains on track, and the new money adds to the approximately $28.4 million it reported for September 30. Pricing release · Preliminary prospectus

H.C. Wainwright is the sole book-running manager and holds a 30-day option to buy up to an additional 180,000 shares at the same price, less its discount. Closing was expected on or about November 5. MediWound said it will use the net proceeds for working capital and general corporate purposes. The prospectus does not earmark any of the money for EscharEx or NexoBrid, gives management broad discretion, and says part could go toward in-licensing or acquisitions, although the company has no current plans for either. Chief Financial Officer Hani Luxenburg is named as the company contact on the release. Pricing release · Preliminary prospectus

What the bank and the lawyers get

The preliminary prospectus left the per share discount blank, and no final prospectus supplement had been posted by November 5. It does list other payments to the underwriter: $100,000 for legal fees, $25,000 for nonaccountable expenses, clearing fees of $15,950 and, at MediWound's sole discretion, a one-time performance bonus of up to $500,000. H.C. Wainwright also gets a 10 month tail on capital from investors it brought over the wall, and it or its designees received warrants as compensation in the 2022 offerings it arranged. Meitar | Law Offices advises the company on Israeli law and Latham & Watkins LLP on U.S. law. Lowenstein Sandler LLP represents the underwriter. MediWound and its directors and executive officers agreed to 60 day lock-ups, though warrant exercises and equity plan grants are carved out. Preliminary prospectus

How fast the cash is going

Preliminary unaudited figures in the prospectus put cash, cash equivalents and deposits at approximately $28.4 million on September 30, compared with $53.6 million at the end of 2025. The company's accountants have not reviewed those numbers. In August, MediWound reported first half cash burn of $20 million. Third quarter revenue is expected at approximately $3.6 million, compared with $5.4 million a year earlier, which the company attributes to lower revenue from development services related to the U.S. government. Preliminary prospectus · Second quarter release

Revenue is the weakest part of the picture. In August the company reaffirmed full year 2026 revenue guidance of $24 million to $26 million, relying on second half contributions from its services agreement with Vericel and other government programs. First half revenue was $4.6 million. The new prospectus says a substantial portion of the revenue anticipated for 2026 relates to development services for a planned U.S. manufacturing facility that is still under discussion with the U.S. government, and that MediWound has limited visibility on when or whether it will be recognized. The prospectus incorporates the August release but specifically excludes the section headed 2026 Revenue Guidance. Second quarter release · Preliminary prospectus

First half research and development expenses rose to $11.1 million from $6.4 million, driven by the Phase III trial, and the operating loss reached $17.4 million. The net loss of $10.3 million was smaller only because of $7.7 million in non-cash warrant revaluation income. In its June 30 financial statements, the company said the $35.8 million it held at that date would fund operations for at least twelve months from their issuance. Second quarter release · June 30 financial statements

What existing holders give up

MediWound had 13,010,217 ordinary shares outstanding on September 30, before the new 1,200,000 and up to 180,000 more under the option. Another 1,479,362 shares sit under options at a weighted average exercise price of $15.79. Net tangible book value was $2.76 per share at June 30, so buyers at $12.50 face immediate dilution. The risk factors also state that the company has no committed external source of funds. Preliminary prospectus

The VALUE Phase III trial of EscharEx in venous leg ulcers targets 216 patients at approximately 40 sites, with an interim sample size reassessment and full enrollment on track for the end of the first quarter of 2027. The independent safety board found no safety concerns. That milestone reviews the trial's size and reports no efficacy result. On NexoBrid, the U.S. Department of War added $3.3 million in non-dilutive funding to a program with a total budget of $21.8 million. MediWound expects to finish changes the EMA requested at its expanded plant in the fourth quarter of 2026, with commercial supply expected in the second half of 2027, subject to approval. Preliminary prospectus

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.